STOCK TITAN

Kura Oncology (KURA) Stock Price, News & Analysis

KURA NASDAQ
Published by Stock Titan Data refreshed

Why is KURA Stock Up Today?

7.08% today
29 alerts
2.3x vol
15m delay

Kura Oncology, Inc. (KURA) CEO Troy Edward Wilson reported purchases totaling 200,000 shares, but the disclosure became public on November 16, before today's trading.

AI-generated explanation by Rhea-AI, written on at . How Rhea-AI works. Not financial advice.

Price Move History

Daily moves over 5%
42 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
-23% close of November 4, 2026
1-year change
-31% closing prices, November 17, 2025 to November 17, 2026
1-month change
-17.5% closing prices, October 16, 2026 to November 17, 2026

Company Description

Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for the treatment of cancer. According to company disclosures, its pipeline consists of small molecule drug candidates that target cancer signaling pathways and are intended to address high-need hematologic malignancies and solid tumors. Kura has advanced from a clinical-stage focus into commercialization with the U.S. Food and Drug Administration (FDA) approval of KOMZIFTI (ziftomenib) for a genetically defined subset of acute myeloid leukemia (AML).

The company’s lead program centers on ziftomenib, an oral menin inhibitor. As described in Kura’s press releases and SEC filings, KOMZIFTI is approved in the United States for the treatment of adult patients with relapsed or refractory AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. KOMZIFTI is characterized as the first and only once-daily, oral menin inhibitor approved for this indication. Kura is developing ziftomenib across the AML treatment continuum, including front-line settings and combination regimens.

Precision oncology focus

Kura states that it is committed to realizing the promise of precision medicines by directing therapies at specific genetic drivers of disease. In AML, the company highlights NPM1 mutations, KMT2A rearrangements and FLT3 mutations as important molecular subtypes under investigation. Its programs are designed to address patients with limited treatment options and high unmet medical need, particularly in hematologic malignancies.

Beyond AML, Kura reports that its pipeline of small molecule drug candidates is designed to target cancer signaling pathways in both blood cancers and solid tumors. The company emphasizes work in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors.

Ziftomenib and KOMZIFTI

Ziftomenib is described as a potent, selective oral menin inhibitor. In company communications and an 8-K filing, Kura notes that the pivotal KOMET-001 trial evaluated KOMZIFTI’s safety and efficacy in adult patients with relapsed or refractory NPM1-mutated AML. Based on these data, the FDA granted full approval of KOMZIFTI for adult patients with relapsed or refractory AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.

Kura and its partner Kyowa Kirin report that KOMZIFTI is being developed further in multiple settings. Ongoing clinical programs include:

  • KOMET-007, a Phase 1a/1b trial evaluating ziftomenib in combination with standard regimens such as cytarabine/daunorubicin ("7+3") and venetoclax/azacitidine in patients with newly diagnosed and relapsed or refractory AML harboring NPM1 mutations or KMT2A rearrangements.
  • KOMET-017, Phase 3 registrational trials designed as global, randomized, double-blind, placebo-controlled studies to evaluate ziftomenib in combination with intensive and non-intensive chemotherapy regimens in patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML.
  • Additional cohorts that explore combinations with FLT3 inhibitors such as quizartinib and gilteritinib in molecularly defined AML populations.

Company updates describe robust clinical activity and a safety profile that Kura characterizes as manageable in combination settings, with particular attention to differentiation syndrome, myelosuppression and QTc interval effects as outlined in the prescribing information and related safety communications.

Farnesyl transferase inhibitor (FTI) programs

In addition to menin inhibition, Kura is advancing farnesyl transferase inhibitors, including darlifarnib (KO-2806) and tipifarnib. The company reports preliminary clinical data from studies such as FIT-001 in renal cell carcinoma and KURRENT-HN in head and neck squamous cell carcinoma, where these FTIs are combined with other targeted therapies. Kura describes these programs as aimed at addressing resistance mechanisms in solid tumors by modulating a common pathway.

Across these efforts, Kura’s stated goal is to develop targeted therapies that can be used alone or in rational combinations to improve outcomes in cancers driven by specific molecular alterations.

Collaboration with Kyowa Kirin

Kura has entered into a global strategic collaboration and license agreement with Kyowa Kirin for the development and commercialization of KOMZIFTI. Under the terms summarized in an 8-K filing, Kura leads development, regulatory and commercial strategy in the United States and is responsible for manufacturing KOMZIFTI, while Kyowa Kirin leads development, regulatory and commercial strategy and commercialization outside the United States. The parties also have a Co-Promotion and Medical Affairs Agreement for co-promotion and shared medical affairs activities for ziftomenib in the United States.

Commercialization of KOMZIFTI

Following FDA approval, Kura reports that KOMZIFTI is commercially available in the United States for prescribers and can be obtained through a limited network of specialty pharmacies and distributors. The company has disclosed a wholesale acquisition cost for a one-month supply of KOMZIFTI in an 8-K filing and has described the initiation of a U.S. commercial launch. Kura also notes the inclusion of KOMZIFTI in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a Category 2A recommended treatment option for adults with relapsed or refractory NPM1-mutated AML.

Pipeline breadth and development strategy

Company press releases describe a development strategy that advances ziftomenib into combinations and earlier lines of therapy, including newly diagnosed AML with NPM1 mutations, KMT2A rearrangements and FLT3 mutations. Kura also reports work on next-generation menin inhibitors and preclinical programs in areas such as diabetes and cardiometabolic diseases, as well as potential applications in solid tumors.

For its FTI programs, Kura has presented data suggesting antitumor activity when FTIs are combined with agents such as PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors in solid tumors, including renal cell carcinoma and head and neck squamous cell carcinoma. These programs are described as part of a broader precision oncology pipeline.

Stock information and regulatory status

According to Kura’s SEC filings, the company’s common stock, with a par value of $0.0001 per share, trades on The Nasdaq Global Select Market under the symbol KURA. The filings also confirm that Kura files periodic and current reports with the U.S. Securities and Exchange Commission, including 8-K reports on material events such as clinical milestones, collaboration agreements and FDA approvals.

Stock Performance

$8.02
+7.08%
+0.53
Last updated: at
-31%
Performance 1 year
$736.9M

Kura Oncology (KURA) closed at $7.49 on November 17, 2026. Over the past 12 months, the price has lost 31.0%.

See what a $1,000 investment in KURA would be worth today

Average down calculator for KURA

KURA Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Kura Oncology has 10 recent news articles, with the latest published on . Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, clinical trial, earnings date, conferences. View all KURA news →

Insider Radar

Net Buyers
90-Day Summary
300,000
Shares Bought
122,394
Shares Sold
14
Transactions
Most Recent Transaction
WILSON TROY EDWARD (President and CEO) bought 101,119 shares held indirectly @ $7.42 on November 16, 2026

Insider buying activity at Kura Oncology over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Kura Oncology generated $67.5M in revenue in FY2025, operating income reached -$303.6M, and net income was -$278.7M. Diluted earnings per share stood at -$3.18. The company generated -$64.1M in operating cash flow. The current ratio was 6.06, measuring current assets divided by current liabilities.

$67.5M
Revenue (FY2025)
-$278.7M
Net Income (FY2025)
-$64.1M
Operating Cash Flow

Upcoming Events

NOV
17
November 17, 2026 Marketing

UBS Biopharma Presentation

Kura presenting at UBS Global Biopharma London on Nov 17, 2026 at 13:20 GMT; live audio webcast via Kura investor website; replay available.
NOV
18
November 18, 2026 Marketing

Jefferies Healthcare Presentation

Kura presenting at Jefferies Global Healthcare on Nov 18, 2026 at 14:30 GMT; live audio webcast via Kura investor website; replay available.
DEC
12
December 12, 2026 - December 15, 2026 Clinical

ASH 2026 Presentations

Kura Oncology and Kyowa Kirin present 8 ziftomenib abstracts (4 oral, 4 posters) at ASH 2026 in New Orleans, Dec 12–15.
H1
2027
H1 2027 Clinical

Darlifarnib study start

Planned darlifarnib registration study to start in H1 2027 for ~40 patients with HRAS‑mutant salivary gland cancer; FDA aligned.
YEAR
2027
2027 Clinical

Combination milestones

Planned renal and pancreatic cancer combination milestones expected during 2027; timing and specifics not yet disclosed.
YEAR
2027
2027 Clinical

Phase 1a trial start

Planned Phase 1a initiation of darlifarnib+daraxonrasib in 2L+ KRAS-mutant pancreatic cancer; site and protocol details TBA.
JAN
02
January 2, 2027 Corporate

25% vesting date

25% of 49,750 options vest one year after vesting commencement; assumes start=2026-01-02.
FEB
02
February 2, 2027 - February 2, 2030 Corporate

Employee options vesting

69,750 inducement options; $8.27 exercise; 25% vests 2027-02-02; monthly vesting through 2030-02-02
MAR
02
March 2, 2027 Corporate

Initial 25% vesting

25% of the Mar 2, 2026 option grants (44,700 shares) vest (cliff).
MAR
02
March 2, 2027 - March 2, 2030 Corporate

Monthly vesting period

Remaining 75% vests monthly from one-year mark through full vesting period.
APR
01
April 1, 2027 - April 1, 2030 Corporate

Option vesting period

25% vests 2027-04-01; monthly vesting through 2030-04-01; 153,750 options, $8.34 exercise
AUG
03
August 3, 2027 Corporate

Options first vesting

25% of 104,500 inducement options vest; exercise price $9.19. Grants to six new employees under 2023 Inducement Option Plan.
AUG
03
August 3, 2027 - August 3, 2030 Corporate

Options monthly vesting

Remaining 75% of 104,500 options vest monthly from 2027-08-03 through 2030-08-03; exercise price $9.19; subject to service.
AUG
12
August 12, 2027 - February 12, 2028 Clinical

Ziftomenib darlifarnib readouts

Multiple ziftomenib and darlifarnib clinical readouts planned Aug 12, 2027–Feb 12, 2028; includes Phase 2/3 data with regulatory and commercial implications.
SEP
01
September 1, 2027 Corporate

One-year option vesting

25% of 48,450 options vest on 2027-09-01 under Kura's 2023 Inducement Option Plan; exercise price $12.89.
NOV
02
November 2, 2027 Corporate

First vesting anniversary

25% of inducement options vest on first anniversary (grant 2026-11-02). Exercise price $9.79; monthly vest thereafter.
YEAR
2028
2028 Clinical

Planned Phase 3 Study

Planned registrational Phase 3 study in 2028 to support approval; initiation contingent on Phase 1b random trial and enrollment.
YEAR
2028
2028 Clinical

KOMET-017 Phase 3 results

Initial Phase 3 KOMET-017 results anticipated in 2028; results could materially affect program valuation and development path.
YEAR
2028
YEAR
2028
2028 Clinical

KOMET-017 Phase 3 topline

Topline Phase 3 KOMET-017 results anticipated in 2028; funded by $180M collaboration
YEAR
2028
2028 Clinical

KOMET-017 Phase 3 topline results

Anticipated topline readout for KOMET-017 Phase 3 (ziftomenib) in 2028; timing approximate, readout will impact program funding.
YEAR
2028
2028 Clinical

KOMET-017 topline data

Topline Phase 3 KOMET-017 results for ziftomenib in AML expected in 2028; pivotal readout will affect commercialization and regulatory plans.
YEAR
2028
2028 Clinical

Planned registrational study

Planned registrational study of darlifarnib plus cabozantinib to start in 2028 worldwide following Phase 1b dose selection.
JAN
02
January 2, 2030 Corporate

Final vesting completion

Remaining 75% vests monthly over next 36 months, completing four-year vesting schedule.
MAR
02
March 2, 2030 Corporate

Options fully vested

All options from Mar 2, 2026 grants fully vested (44,700 shares total).
SEP
01
September 1, 2030 Corporate

Full option vesting

Remaining 75% vests monthly over 36 months; full vesting of 48,450 options completes on 2030-09-01.
NOV
02
November 2, 2030 Corporate

Final vesting date

Remaining inducement options fully vested four years after grant (2026-11-02). Monthly vesting occurred after first anniversary.

Kura Oncology has 27 upcoming scheduled events. Investors can track these dates to stay informed about potential catalysts that may affect the KURA stock price.

Short Interest History

Last 12 Months

Short interest in Kura Oncology (KURA) currently stands at 12.6 million shares, down 11.7% from the previous reporting period, representing 14.1% of the float. Since November 2025, short interest has increased by 58.2%.

Days to Cover History

Last 12 Months

Days to cover for Kura Oncology (KURA) currently stands at 7.9 days, down 8.4% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 59.1%. Across the settlements charted above, it has ranged from 4.8 to 11.8 days.

KURA Company Profile & Sector Positioning

Kura Oncology (KURA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing KURA often look at related companies in the same sector, including Nuvectis Pharma, Inc. (NVCT), ArriVent BioPharma, Inc. (AVBP), Syndax Pharmaceuticals, Inc. (SNDX), Rigel Pharmaceuticals Inc. (RIGL), and Aura Biosciences, Inc. (AURA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate KURA's relative position within its industry.

Frequently Asked Questions

The current stock price of Kura Oncology (KURA) is $8.02 as of November 18, 2026.

The market cap of Kura Oncology (KURA) is approximately $736.9M. Learn more about what market capitalization means .

The FY2025 revenue of Kura Oncology (KURA) is $67.5M, from its most recent completed fiscal year.

The FY2025 net income of Kura Oncology (KURA) is -$278.7M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Kura Oncology (KURA) is -$3.18 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Kura Oncology (KURA) is -$64.1M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Kura Oncology (KURA), current assets divided by current liabilities, was 6.06 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Kura Oncology (KURA) is -$303.6M for FY2025, its most recent completed fiscal year. Learn about operating income.

Kura Oncology focuses on developing precision medicines for cancer. The company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors.

Kura targets hematologic malignancies such as acute myeloid leukemia and solid tumors. Its menin inhibitor ziftomenib is focused on genetically defined AML subtypes, while its farnesyl transferase inhibitor programs are being studied in solid tumors including renal cell carcinoma and head and neck squamous cell carcinoma.

KOMZIFTI (ziftomenib) is approved in the United States for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.

Ziftomenib is being evaluated in multiple trials, including KOMET-007 and KOMET-017, in combination with intensive and non-intensive chemotherapy and with agents such as venetoclax, azacitidine and FLT3 inhibitors in newly diagnosed and relapsed or refractory AML with specific genetic alterations.

Kura is developing farnesyl transferase inhibitors such as darlifarnib (KO-2806) and tipifarnib. These agents are being studied in combination with other targeted therapies in solid tumors, with the goal of addressing mechanisms of adaptive and innate resistance.

Kura has a global strategic collaboration with Kyowa Kirin for KOMZIFTI. Kura leads development, regulatory and commercial strategy in the United States and is responsible for manufacturing, while Kyowa Kirin leads development, regulatory and commercial strategy and commercialization outside the United States.

Yes. According to its SEC filings, Kura Oncology’s common stock is listed on The Nasdaq Global Select Market under the ticker symbol KURA.

Kura describes its approach as developing small molecule drugs that target specific genetic drivers of disease, such as NPM1 mutations, KMT2A rearrangements and FLT3 mutations in AML, and resistance pathways in solid tumors, to improve outcomes in defined patient populations.